Loading...
•
Dec 31, 2023
Jazz Pharmaceuticals Q4 2023 Earnings Report
Jazz Pharmaceuticals announced its Q4 2023 financial results, demonstrating revenue growth and strategic pipeline advancements.
Key Takeaways
Jazz Pharmaceuticals reported a strong Q4 2023, achieving its first $1 billion revenue quarter, driven by key growth drivers like Xywav, Epidiolex, and Rylaze. The company's oncology revenue surpassed $1 billion in 2023, and they anticipate multiple late-stage pipeline catalysts in 2024.
Achieved first $1 billion revenue quarter.
Xywav net product sales increased 20% year-over-year in Q4 2023.
Epidiolex/Epidyolex net product sales increased 16% year-over-year in Q4 2023.
Rylaze net product sales increased 26% year-over-year in Q4 2023.
Jazz Pharmaceuticals
Jazz Pharmaceuticals
Jazz Pharmaceuticals Revenue by Segment
Revenue by Segment
Other Revenue
CapyFin.com Forward Guidance
Jazz Pharmaceuticals provided full year 2024 financial guidance, expecting revenues between $4.0 and $4.2 billion. Neuroscience revenue is projected between $2.8 and $2.95 billion, and Oncology revenue between $1.12 and $1.22 billion.
Positive Outlook
- Total revenue guidance of $4.0 to $4.2 billion.
- Neuroscience revenue guidance of $2.8 to $2.95 billion.
- Oncology revenue guidance of $1.12 to $1.22 billion.
- Non-GAAP gross margin % of 93%
- Non-GAAP net income between $1.275 and $1.350 billion
Challenges Ahead
- GAAP Gross margin % of 89%
- GAAP SG&A expenses between $1.346 and $1.426 billion.
- GAAP R&D expenses between $877 and $935 million.
- GAAP Effective tax rate between (22)% and (3)%.
- Net income between $385 and $530 million.